Ex-Abbott exec joins Nutromics as its first CMO

Date:

Share:

Australian med tech startup Nutromics has named US-based Dr Agim Beshiri as its first chief medical officer.

Dr Beshiri has over two decades of experience in the diagnostic space, specialising in laboratory medicine and internal medicine. He was recently a senior medical director at Abbott Laboratories, the maker of the Freestyle Libre and Lingo biosensors. 

He will be leading ​​Nutromics’ medical research, regulatory engagement, clinical development, and hospital partnerships, according to a media release.

Nutromics was on the lookout for a CMO who could challenge them and ensure that the company stays true to its values while pursuing “extraordinary” technology.

“Dr Beshiri is a world-class hire and a fantastic start in our US hiring drive. Having him join Nutromics is a testament to the potential of our technology, especially in its ability to close major gaps in unmet clinical needs,” said Nutromics co-founder and co-CEO Hitesh Mehta.

WHY IT MATTERS

Dr Beshiri’s appointment comes as Nutromics is set to conduct in-human clinical studies of its “lab-on-the-skin” patch. The patch is a continuous molecular monitoring (CMM) device that can track multiple targets in the human body and provide real-time molecular-level insights for remote patient monitoring and hospital-at-home systems. Last year, the company received A$10 million in investments to fund its trials.

As a senior medical device executive, Dr Beshiri has expertise in developing and implementing diagnostic research for biomarkers. “I am excited to play my part in transforming Nutromics’ innovative technology into a clinically implementable technology in a clinician’s hands,” he said.

THE LARGER TREND

Nutromics is eyeing to enter the therapeutic drug monitoring (TDM) market with its first CMM device for tracking vancomycin, a prescription antibiotic. It is expected that the global TDM market will reach $2 billion in value by 2025 from $1.4 billion in 2020, growing at a 6.9% CAGR.

The company aims to secure the approval of the US Food and Drug Administration for its CMM device for vancomycin by 2025.

━ more like this

23andMe posts $217M net loss during ‘transitional’ fiscal year

23andMe reported a $217 million net loss during its fiscal year 2022, which ended March 31, compared with $184 million during the prior year.  The...

Study: VR therapeutic reduces pain intensity long term, compared with sham app

A virtual reality therapeutic program reduces pain intensity up to six months later, compared with a sham app, according to a study published in...

Roundup: Telehealth platform for endometriosis launched in Malaysia, India upgrades health ID app, and more briefs

Bayer launches telehealth platform for endometriosis in Malaysia Pharmaceutical firm Bayer has partnered with digital health company DoctorOnCall and the Endometriosis Association of Malaysia (MyEndosis)...

Clinical trial tech company uMotif scores $22.5M to continue international expansion

Patient data capture and clinical trial tech company uMotif announced Wednesday it had secured $25.5 million from a fund managed by Athyrium Capital Management. The...

Transcarent hires chief marketing officer from Fitbit and more digital health hires

Transcarent, a healthcare platform focused on self-insured employers, has appointed Tim Rosa as chief marketing officer. Rosa comes to Transcarent from health-tracking wearable maker Fitbit,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here